We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Everolimus with endocrine therapy as a treatment option in ER + MBC failing at least one line of endocrine therapy: a single institute experience.
- Authors
Jaafar, H.; Elzain, R.; Alqawasmeh, K.; Trad, D.; Jaloudi, M.
- Abstract
75% of MBC are hormone receptor positive; on ET the responders eventually will acquire resistance. One of the suggestive mechanisms for this resistance is the activation of the mTOR pathway. In the BOLERO-2 study, the addition of everolimus to exemestane was associated with a significant improvement in PFS. Purpose and Methods: To evaluate the response rate in heavily pretreated population and the safety of the drug in different genetic/ethnic backgrounds. We performed a retrospective analysis of all ER+, MBC who received everolimus during a period of 6 months. A few cases were reported based on their interesting findings. Results: 19 patients, Median age was 58, 26% were pre-menopause. The combination was used after failure of at least one line of ET (1-4), 17 patients had it with exemestane and 2 with tamoxifen. The median duration of the treatment was 20 weeks. 8 had it for ⩽ 4weeks. The reasons were poor patient selection (PS ⩾3), poor tolerance or progressive disease. Response assessment, 10 had PR, 2 SD, 1 PD, in 6 patients no evaluation was possible for premature stoppage of the therapy. Toxicities: mucositis 78%. Less frequently hyperglycemia, weight loss, infection and non-infectious pneumonitis. Dose interruptions and adjustments were frequently reported >70%. Conclusions: Everolimus combination was associated with a high RR, it may be less toxic than chemotherapy, but patients who are poor candidates for chemotherapy may not be a good candidates for this combination as well, Educating patients and physicians experience reduce the treatment toxicity and improve the tolerability.
- Subjects
EVEROLIMUS; HORMONE therapy; HORMONE receptors; TREATMENT of drug toxicity; MEDICATION safety; TREATMENT effectiveness; DOSE-effect relationship in pharmacology
- Publication
Pan Arab Journal of Oncology, 2014, Vol 7, Issue 2, p24
- ISSN
2070-254X
- Publication type
Article